HepaRegeniX GmbH Raises €9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of
January 5, 2017
Tubingen (Germany), January 05, 2017
HepaRegeniX GmbH, a new Biotech company developing innovative treatments for liver diseases, announced today the completion of a €9 million Series A financing. The round was led by Boehringer Ingelheim Venture Fund GmbH (BIVF) and Novo Seeds, and complemented by the High-Tech Gruenderfonds and coparion.
HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany. In the healthy liver, hepatocytes have a near endless capacity to regenerate. However, in liver diseases, this regenerative capacity is locked and excessive hepatocyte death cannot be compensated, ultimately leading to loss of liver function and often death.